

**FORMATO
EUROPEO PER IL
CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome **NICOLETTI FERDINANDO**
Indirizzo
Telefono
Fax
E-mail

Nazionalità Italiana
Data di nascita

ESPERIENZA LAVORATIVA

- Date (2006-oggi) Professore Ordinario di Scienze Tecniche di Medicina di Laboratorio (MED46) dal 2007 al 2016. Dal 2016 ad oggi Prof. Ordinario di Patologia Generale
Università degli Studi di Catania
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Date (2001-2006) Professore Associato di Patologia Generale
Università degli Studi di Catania
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Date (1991-2001) Ricercatore presso Facolta' Di Medicina E Chirurgia
Universita' Degli Studi Di Milano.
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

ISTRUZIONE E FORMAZIONE

- Date (1986-1990)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)
 - Date (1981-1987)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

Specializzazione in Allergologia e Immunologia Clinica

Istituto di Medicina Interna, Malattie Infettive e Immunopatologia dell'Università di Milano

Laurea in Medicina e Chirurgia
Università degli Studi di Catania

110/110 e lode

CAPACITÀ E COMPETENZE PERSONALI

MADRELINGUA

ITALIANO

ALTRE LINGUA

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

INGLESE

ECCELLENTE

ECCELLENTE

ECCELLENTE

ALTRE LINGUA

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

SPAGNOLO

ECCELLENTE

ECCELLENTE

ECCELLENTE

CAPACITÀ E COMPETENZE RELAZIONALI

FERDINANDO NICOLETTI È CONSULENTE ESTERNO DEL RIGHSOSPITALET UNIVERSITY HOSPITAL, COPENHAGEN, DANIMARCA, DAL 1999. E' STATO VISITING PROFESSOR PRESSO LA FACOLTÀ DI MEDICINA DELL'UNIVERSITÀ DI BELGRADO, SERBIA, NEL FEBBRAIO 2004.

CAPACITÀ E COMPETENZE ORGANIZZATIVE

FERDINANDO NICOLETTI È STATO

- VICE-PRESIDENTE DEL COMITATO ETICO DELL'OSPEDALE CANNIZZARO DI CATANIA NEL CORSO DEL 2009.
- PRESIDENTE DELLO IACUC DELL'UNIVERSITÀ DEGLI STUDI DI CATANIA FINO AL 2014.
- COFONDATORE DI GANIAL IMMUNOTHERAPEUTICS (DELAWARE),
- CSO E FONDATORE DI ONCONOX APS (COPENHAGEN, DANIMARCA. WWW.ONCONOX.COM)
- COFONDATORE DI AURA BIOPHARM (OSLO, NORWAY WWW.AURABIOPHARM.COM)

CAPACITÀ E COMPETENZE
TECNICHE

- HA LAVORATO NEL CAMPO DELLA IMMUNOLOGIA CELLULARE E MOLECOLARE, IMMUNOFARMACOLOGIA, TOSSICOLOGIA E ONCOLOGIA SPERIMENTALE.
- HA PUBBLICATO OLTRE 230 LAVORI IN RIVISTE SCIENTIFICHE.
- HA COLLABORATO ALLE ATTIVITÀ DI R&D IN STUDI PRECLINICI E CLINICI CON AZIENDE FARMACEUTICHE E DI BIOTECNOLOGIE, TRA CUI ALFAMA (LISBONA, PORTOGALLO), COSMO BIOTECH (MILANO/SAN DIEGO), HOFFMAN-LA ROCHE (BASILEA, SVIZZERA), MERCK SERONO INTERNATIONAL SA (GINEVRA, SVIZZERA), MERCK-SCHERING-PLOUGH (NEW JERSEY, USA), NOVARTIS (BASILEA, SVIZZERA), PFIZER-WYETH (NY, USA), SANOFI-AVENTIS (LABEGE, FRANCIA).
- E' REVISORE PER NUMEROSE RIVISTE DI GRANDE IMPATTO TRA CUI CANCER RESEARCH, DIABETOLOGIA, DIABETES E PNAS ED È NEL COMITATO EDITORIALE DELLE SEGUENTI RIVISTE: INT. J. MOLECULAR MEDICINE, INT. J. OF ONCOLOGY, RECENT PAT ANTIINFECT DRUG DISCOV, JOURNAL OF CARCINOGENESIS.
- FA PARTE DELL' EDITORIAL BOARD DI EUROPEAN JOURNAL OF PHARMACOLOGY, INTERNATIONAL JOURNAL OF CANCER, INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, ONCOLOGY REPORTS, JOURNAL OF CARCINOGENESIS, AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY.
- PROF. FERDINANDO NICOLETTI E' INCLUSO TRA I TOP ITALIAN SCIENTIST (www.topitalianscientists.org/) VIA ACADEMY CON HIRSH INDEX (SCOPUS) DI 43

PATENTE O PATENTI B

ULTERIORI INFORMAZIONI

Brevetti

- 1) Nicoletti F (2010). Antitumor Properties Of No Modified Protease Inhibitors. Wo/2010/012466
- 2) Nicoletti F, Al Abed Y, Garotta G (2007). (S,R)-3-Phenyl-4,5 Dihydro-5-Isoxazole Acetic Acid – Nitric Oxide And Use Thereof As Anti-Cancer And Antiviral Agent. Wo/2008/138516
- 3) Bakhutashvili V, Haller J D, Bakhutashvili I, Bakhutashvili A, Nicoletti F, Thiry M, Poncin (2006). Amniotic-Derived Peptide And Uses Thereof. Us20070123467
- 4) Nicoletti F (2006). Compounds Having Immunomodulator Activity. Wo/2006/097273
- 5) Salvaggio A, Nicoletti F, Macri' B (2006). Use Of Uk114 In The Treatment Of Leishmaniasis. Us20060100142

Pubblicazioni

- 1) Nicoletti F, Speciale C, Sortino MA, Panetta MS, Di Giorgio RM, Canonico PL.: Estrogen effects on nigral glutamic acid decarboxylase activity: a possible role for catecholesterogen. *Eur J Pharmacol.* 1985 Sep 24;115(2-3):297-300
- 2) Nicoletti G., Olivieri S., Cammarata E., Nicoletti F., Tempera G.: Le infezioni microbiche nel tossicodipendente. *Giornale di Batteriologia, Virologia ed Immunologia*, 1986, LXXIX, 124-143
- 3) Nicoletti F., Di Mauro M., Stracuzzi S., Pane F., Steinsvag P.L.: Pevalenza di ICA e CF-ICA in familiari di diabetici di tipo 1. *Rassegna di Medicina Interna*, 1988, IX, 3-7
- 4) Lunetta M., Di Mauro M., La Bella G., Buttiglieri R., Nicoletti F.: The quick-acting effect of regular insulin is preserved in premixed protamine and soluble human insulin preparations. *Med. Sci. Res.* 17, 897-898, 1989.
- 5) Nicoletti F. Barcellini W., Di Mauro M., Steinsvag P.O., Lunetta M., Scalia G., Condorelli F., Stivala A.: Correlazione tra anticorpi anti betacellula pancreatica e anti cytomegalovirus in collaterali sani di diabetici di tipo 1. *G. Ital. Diabetol.*, 1989, 9, 165-166.
- 6) Nicoletti F., Meroni P.L., Barcellini W., Steinsvag P.O., Di Mauro M., Lunetta M., Pagano M., Consoli U., Zanussi C.: Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. *Immunology Letters* 23, 211-216, 1989/90.
- 7) Nicoletti F., Caruso M., Di Mauro M., Stracuzzi S., Mancuso M., Scuderi G., Leonardi C., Pagano M., Lunetta M.: CD3+CD25+ cells, CD3+CD4+/CD3+CD8+ ratio, HLA alloantigen association and ICA in type 1 (insulin-dependent) diabetes. *Med. Sci. Res.* 18, 679-681, 1990.
- 8) Nicoletti F., Scalia G., Lunetta M., Condorelli F., Di Mauro M., Barcellini W., Stracuzzi S., Pagano M., Meroni P.L.: Correlation between islet cell antibodies and anti cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients. *Clin. Immunol. Immunopathol.*, 55, 139-147, 1990.
- 9) Nicoletti F., Meroni P.L., Landolfo S., Gariglio M., Guzzardi S., Barcellini W., Lunetta M., Mughini L., Zanussi C.: Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. *Lancet* 336, 319, 1990.
- 10) Barcellini W., Borghi M.O., Nicoletti F., Bonara P., Fain C., Meroni P.L. Combination of mutant EL-4 thymoma cells and EBV-infection in B lymphocyte activation a) EBV-infection of EL-4-activated lymphocytes. b) Use of EL-4 cells as feeders for lymphoblastoid cell lines. *J. Clin. Lab. Immunol.*, 33, 21-28, 1990.
- 11) Nicoletti F., Scalia G., Condorelli F., Stivala A., Leonardi C., Mattina A., Steinsvag P.O., La Rosa L., Lunetta M.: Anti-cytomegalovirus IgM and IgG antibodies, islet cell antibodies and gamma interferon serum levels in newly diagnosed IDDM patients. *Int. J. Immunopathol. Pharmacol.*, 4, 99-106, 1991.
- 12) Nicoletti F., Consoli U., Calogero D., Speciale A.M., Di Marco R., Leonardi C., La Rosa L., Lunetta M., Di Cataldo A., Meroni P.L.: Enhanced percentage of Leu M3+DR+ and Leu M3+CD25+ cells in newly diagnosed IDDM patients. *Autoimmunity*, 9, 255-259, 1991.
- 13) Nicoletti F., Meroni P.L., Barcellini W., Grasso S., Borghi M.O., Lunetta M., Di Marco R., Stefani S., Mughini L.: FK-506 prevents diabetes in diabetes-prone BB/Wor rats. *Int. J. Immunopharmacol.* 13, 1027-1030, 1991.
- 14) Nicoletti F., Meroni P.L., Lunetta M., Vigo R., Palermo T., Papalia D., Barcellini

- W., Di Mauro M., Caruso-Nicoletti M., Mughini L., Zanussi C.: Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. *Lancet* 337, 1292, 1991.
- 15) Lunetta M., Di Mauro M., Nicoletti F., Mughini L.: Diabetogenic effect of naloxone in subjects with impaired glucose tolerance. *Med. Sci. Res.* 19, 737-738, 1991.
- 16) Barcellini W., Borghi M.O., Fain C., Del Papa N., Nicoletti F., Meroni P.L. Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. *Clin Immunol. Immunopathol.*, 65, 39-44, 1992.
- 17) Nicoletti F. Meroni P.L., Di Marco R., Grasso S., Barcellini W., Borghi M.O., Lunetta M., Mughini L., Menta R., Schorlemmer H.U., Zanussi C. The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. *Scand. J. Immunol.*, 36, 415-420, 1992
- 18) Nicoletti F., Meroni P.L., Di Marco R., Barcellini W., Borghi M.O., Gariglio G., Mattina A., Grasso S., Landolfo S. In vivo treatment with monoclonal antibody to interferon-gamma neither affects the survival nor the rate and onset of lupus nephritis in the MRL/lpr-lpr mouse. *Immunopharmacology*, 24, 11-16, 1992.
- 19) Del Papa N., Meroni P.L., Barcellini W., Sinico A., Radice A., Tincani A., D'Cruz D., Nicoletti F., Borghi M.O., Khamashta M.A., Huges G.R.V., Balestrieri G. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. *Clin. Immunol. Immunopathol.* 63, 267-274, 1992.
- 20) Borghi M.O., Barcellini W., Fain C., Nicoletti F., Del Papa N., Licciardello L., Meroni P.L.: In vitro effect of MSD53 and its fractions on human mononuclear cells. *Int. J. Immunother.*, 8, 77-84, 1992.
- 21) Di Marco R., Condorelli F., Girardello R., Uslenghi C., Chisari G., Di Mauro M., Speciale A.M., Meroni P.L., Nicoletti F. Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod. *Scand. J. Infect. Dis.* 24, 821-823, 1992
- 22) Lunetta M., Di Mauro M., Nicoletti F., Mughini L.: Effects of naloxone on immunoreactive insulin and C-peptide response to intravenous glucagon in obese women. *Med. Sci. Res.* 21, 211-212, 1993.
- 23) Grasso AA, Reggio A, Marano P, Florio S, Scordino N, Cappello S, Nicoletti F.: Epidemiological survey of multiple sclerosis in Catania city. *Ital J Neurol Sci.* 1992 May;13(4):301-9.
- 24) Barcellini W., Borghi M.O., Fain C., Nicoletti F., Menta R., Meroni P.L., Schorlemmer H.U., In vitro effects of deoxyspergualin (DSO) on human peripheral blood mononuclear cells. *EOS*, 13, 14-15, 1993.
- 25) Di Marco R., Carrabba I., Cavallaro V., Zaccone P., Stazzone C., Franco S., Cocuzza C., Nicoletti G., Nicoletti F.: The effect of cefepime on some immune parameters in vitro: lack of interference with mitogen-induced lymphoproliferation, immunoglobulin synthesis, IFN-gamma and IL-2 secretion and IL-2 receptor expression. *J.Chemother.* 5, 297-301, 1993.
- 26) Nicoletti F., Borghi M.O., Meroni P.L., Barcellini W., Fain C., Di Marco R., Menta R., Schorlemmer H.U., Bruno G., Magro G., Grasso S.: Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. *Clin. Exp. Immunol.* 91, 232-236
- 27) Tang H., Mignon-Godefroy K., Meroni P.L., Garotta G., Charreire J., Nicoletti F. The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. *Eur. J. Immunol.* 23 275-278, 1993
- 28) Nicoletti F., Di Marco R., Barcellini W., Magro G., Schorlemmer H.U., Kurrle R., Lunetta M., Grasso S., Zaccone P., Meroni P.L. :Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. *Eur. J. Immunol.* 24 1843-1847, 1994
- 29) Nicoletti F., Di Marco R., Morrone S., Zaccone P., Lembo D., Grasso S., Santoni A., Meroni P.L. Bendtzen K. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. *Immunology.* 81, 317-321, 1994
- 30) Nicoletti F., Di Marco R., Barcellini W., Borghi M.O., Lunetta M., Mughini L., Meroni P.L., Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. *Scand.J.Immunol.* 39, 333-336, 1994
- 31) Borghi M.O., Fain C., Barcellini W., Del Papa N., La Rosa L., Nicoletti F., Uslenghi C., Meroni P.L. Ex vivo effects of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population. *Int.J. Immunother.*, X, 35-39, 1994
- 32) Barcellini W., Brando B., Borghi M.O., Fain C., Rizzardi G.P., Nicoletti F., Meroni

- P.L. Mutant EL-4 B5 subclone activation system: cytofluorimetric analysis of B lymphocyte surface markers. *J. Clin. Lab. Immunol.*, 43, 51-67, 1994
- 33) Nicoletti F., Zaccone P., Magro G., Barcellini W., Cavallaro V., Belli G., Cocuzza C., Di Marco R., Meroni P.L. The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse. *Scand. J. Immunol.* 40, 549-56, 1994
- 34) Biondi, R., Reggio, A., Sofia, V., Patti, F., Nibali, G., De Pascalis, D., Nicoletti, F. Epilepsy and multiple sclerosis [EPILESSIA E SCLEROSI MULTIPLA]. *Bollettino - Lega Italiana contro l'Epilessia Issue 86-87, 1994, Pages 205-206*
- 35) Piona A., La Rosa L., Tincani A., Faden D., Magro G., Grasso S., Nicoletti F., Balestrieri G., Meroni P.L.: Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti cardiolipin antibodies in pregnant naive BALB/c mice. *Scand J Immunol.*, 41, 427-32, 1995
- 36) Boissier M.C., Chiocchia G., Bessis N., Hajnal J., Garotta G., Nicoletti F., Fournier C. TI: Biphasic effect of interferon gamma in murine collagen induced arthritis. *Eur J Immunol.* 25, 1184-1190, 1995
- 37) Nicoletti F., Zaccone P., Di Marco R., Magro G., Grasso S., Morrone S., Santoni A., Tempera G., Meroni P.L., Bendtzen K.: Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. *Immunology*, 85, 645-650, 1995
- 38) Patti F, Di Stefano M, De Pascalis D, Ciancio MR, De Bernardis E, Nicoletti F, Reggio A.: May there exist specific MRI findings predictive of dementia in multiple sclerosis patients? *Funct Neurol.* 1995 Mar-Apr;10(2):83-90.
- 39) Barcellini W., Rizzardi G.P., Borghi M.O., Nicoletti F., Fain C., Del Papa N., Meroni P.L.: In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. *Lupus*, 5, 139-145, 1996
- 40) Nicoletti F., Patti F., Di Marco R., Zaccone P., Nicoletti A., Meroni P.L., Reggio A. Circulating levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. *Cytokine*, 8, 395-400, 1996
- 41) Genovese F., Mancuso G., Cuzzola M., Cusumano V., Nicoletti F., Bendtzen K., Teti G.: Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. *Antimicrobial Agents and Chemotherapy*, 40, 1733, 1996
- 42) Di Marco R., Zaccone P., Magro G., Grasso S., Lunetta M., Barcellini W., Nicolosi V.M., Meroni P.L., Nicoletti F. Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats. *Clin. Exp. Immunol.*, 105, 338-343, 1996
- 43) Nicoletti F., Borghi M.O., Barcellini W., Fain C., Beltrami B., Del Papa N., Schorlemmer H.U., Mottola R., Meroni P.L.: Immunosuppressive activity of 15-Deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. *Eur. J. Pharmacol.*, 311, 213-220, 1996
- 44) Lunetta M., Di Mauro M, Le Moli R., Nicoletti F. Effect of octreotide on blood glucose, and counterregulatory hormones in insulin-dependent diabetic patients: The role of dose and route of administration. *Eur. J. Clin. Pharmacol.*, 51, 139-144, 1996
- 45) Nicoletti F., Patti F., Cocuzza C., P. Zaccone P., Nicoletti A., Di Marco R., Reggio A. Elevated serum levels of IL-12 in chronic progressive multiple sclerosis. *Journal of Neuroimmunology*, 70, 87-90, 1996
- 46) Nicoletti F., Meroni P.L. Bendtzen K. Fucidic acid and insulin-dependent diabetes mellitus. *Autoimmunity*, 24, 187-197, 1996
- 47) Nicoletti F., Zaccone P., Di Marco R., et al. The effects of a nonimmunogenic form of murine soluble interferon-g receptor on the development of autoimmune diabetes in the NOD mouse. *Endocrinology*, 137: 5567-5575, 1996
- 48) Nicoletti F., Zaccone P., Di Marco R., Lunetta M., Magro G., Grasso S., Meroni PL. and Garotta G. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. *Endocrinology*, 138: 281-288, 1997
- 49) Nicoletti F., Mancuso G., Cusumano V., Di Marco R., Zaccone P., Bendtzen K. and Teti G. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. *Eur. J. Immunol.*, 27: 1580-1583, 1997
- 50) Doth M., Fricke M., Nicoletti F., Garotta G., Van Velthuysen M.-L., Bruijn J.A. and Gleichman E. Genetic differences in immune reactivity to mercuric chloride (HgCl₂): immunosuppression of H-2d mice is mediated by interferon-gamma (IFN-gamma). *Clin. Exp. Immunol.*, 109: 149-156, 1997
- 51) Nicoletti F., Beltrami B., Raschi E., Di Marco R., Magro G., Grasso S., Bendtzen

- K., Fiorelli G., Meroni PL. Protection from concanavalin A (ConA)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. *Clin. Exp. Immunol.*, 110: 479-484, 1997
- 52) Lunetta M., Di Mauro M., Le Moli R. and Nicoletti F. Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 diabetic patients. *Diab. Res. Clin. Pract.*, 38: 81-89, 1997
- 53) Nicoletti F., Mancuso G., Anzani Ciliberti F., Beninati C., Carbone M., Franco S., and Cusumano V. Endotoxin-induced lethality in neonatal mice is counteracted by interleukin-10 (IL-10) and exacerbated by anti-IL-10. *Clin.Diagn.Lab. Immunol.*, 4: 607-610, 1997
- 54) Cocuzza C., Blandino G., Mattina R., Nicoletti F., and Nicoletti G. Antibiotic susceptibility of group A streptococci in 2 Italian cities : Milano and Catania. *Microb. Drug. Resist.*, 1997, 3 : 379-384
- 55) Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.: Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients. *Diabetes Metab.* 1997 Dec;23(6):524-7
- 56) Nicoletti F., Zaccone P., Di Marco R., Magro G., Grasso S., Stivala F., Calori G., Mughini L., Meroni PL. and Garotta G. Paradoxical antidiabetogenic effect of gamma-Interferon in DP-BB rats. *Diabetes*, 47:32-38, 1998
- 57) Itoh M., Yano A., Xie Q., Iwahashi K., Takeuchi Y., Meroni PL. and Nicoletti F. Essential pathogenic role for endogenous interferon-gamma (IFN-gamma) during disease onset phase of murine experimental autoimmune orchitis, I In vivo studies. *Clin. Exp. Immunol.*, 111: 513-520, 1998
- 58) Di Marco R., Zaccone P., Condorelli L., Leonardi C., Caccamo F., Di Mauro M., Meroni P., and Nicoletti F. Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-alpha. *Immunology Letters.*, 61: 63-66, 1998
- 59) Ikematsu W., Luan F.L., La Rosa L., Beltrami B., Nicoletti F., Buyon J.P., Meroni PL., Balestrieri G., and Casali P. Human anticardiolipin monoclonal antibodies cause placental necrosis and fetal loss in BALB/c mice. *Arthr. Rheum.*, 41: 1026-1039, 1998
- 60) Nicoletti F., Di Marco R., Patti F., Reggio E., Nicoletti A., Zaccone P., Stivala F., Meroni PL., and Reggio A. Blood levels of transforming growth factor-beta 1 (TGF-beta 1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta-1b (IFN-beta 1b). *Clin. Exp. Immunol.*, 113: 96-99, 1998
- 61) Nicoletti F., Nicoletti A., Giuffrida S., Di Marco R., Meroni PL., Bendtzen K., Lunetta M. Sodium fusidate in Guillain-Barré syndrome: a case report. *J. Neurol. Neurosurg. Psychiatry*, 65: 266-268, 1998
- 62) Amital H., Levi Y., Blank M., Barak V., Langevitz P., Afek A., Nicoletti F., Koplovic J., Gilburd B., Meroni PL., and Shoenfeld Y. Immunomodulation of murine experimental SLE-like disease by interferon-gamma. *Lupus*, 7: 445-454, 1998
- 63) Calogero AE., Nicoletti F., Palumbo MA., Burrello N., Di Mauro M., Lunetta M., Bendtzen K., and Cianci A. Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin-6 and low levels of granulocyte-macrophage colony-stimulating factor. *Cytokine*, 10: 814-818, 1998
- 64) Xiang M., Zaccone P., Di Marco R., Magro S., Di Mauro M., Beltrami B., Meroni PL., and Nicoletti F. Prevention by rolipram of concanavalin A-induced T-cell dependent hepatitis in mice. *Eur. J. Pharmacol.*, 367: 399-404, 1999
- 65) La Mantia I., Grillo C., Mattina T., Zaccone P., Xiang M., Di Mauro M., Meroni PL., and Nicoletti F. Prophylaxis with the novel immunomodulator Pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. *J. Chemother.*, 11: 126-130, 1999
- 66) Brazillet M-P., Batteux F., Abeshira-Amar O., Nicoletti F., and Charreire J. Induction of experimental autoimmune thyroiditis by heat-denatured porcine thyroglobulin: a Tc1-mediated disease. *Eur. J. Immunol.*, 29: 1342-1352, 1999
- 67) Xiang M., Zaccone P., Di Marco R., Harris R., Magro G., Di Mauro M., Meroni PL., Garotta G., and Nicoletti F. Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. *Autoimmunity*, 30: 71-80, 1999
- 68) Zaccone P., Phyllips J., Conget I., Gomis R., Haskins K., Minty A., Bendtzen K., Cooke A., and Nicoletti F. Interleukin-13 prevents autoimmune diabetes in NOD mice.

Diabetes, 48: 1522-1529, 1999

69) Panerai AE., Sacerdote P., Bianchi M., Nicoletti F., Manfredi B., Gaspani L., Bartorelli A., Ceciliani F., Ronchi S. Chronic administration of UK-114, a multifunctional emerging protein, modulates the Th1/Th2 cytokine pattern and experimental autoimmune diseases. *Ann. NY Acad. Sci.*, 876 : 229-235, 1999

70) Nicoletti F., Di Marco R., Zaccone P., Magro G., Di Mauro M., Grasso S., and Meroni PL. Endogenous interleukin-12 only plays a key pathogenetic role in NOD mouse diabetes during the very early stage of the disease. *Immunology*, 97: 367-370, 1999

71) Zaccone P., Hutchings P., Nicoletti F., Penna G., Adorini L., and Cooke A. The involvement of IL-12 in murine experimentally induced autoimmune thyroid disease. *Eur. J. Immunol.*, 29: 1933-1942, 1999

72) Di Marco R., Khademi M., Wallstrom E., Muhallab S., Nicoletti F., and Olsson T. Amelioration of experimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement of IL-10. *J. Autoimmun.*, 13: 187-195, 1999

73) Nicoletti F., Zaccone P., Conget I., Gomis R., Moller C., Meroni PL., Bendtzen K., Trepicchio W., and Sandler S. Early prophylaxis with recombinant human Interleukin-11 prevents spontaneous diabetes in NOD mice. *Diabetes*, 48: 2333-2339, 1999

74) Nicoletti F., Patti F., Nicoletti A., L'Episcopo MR., Di Marco R., Bendtzen K., and Reggio A. Sodium fusidate in steroid resistant relapses of multiple sclerosis. *Multiple Sclerosis*, 5 : 377, 1999

75) Di Marco R., Xiang M., Zaccone P., Leonardi C., Franco S., Meroni PL., and Nicoletti F. Concanavalin A-induced hepatitis in mice is prevented by Interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. *Autoimmunity*, 31 : 75-83, 1999

76) Nicoletti F., Di Marco R., Zaccone P., Xiang M., Magro G., Grasso S., Morrone S., Santoni A., Shoenfeld Y., Garotta G., and Meroni PL. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. *Eur. J. Immunol.*, 30 : 438-447, 2000

77) Nicoletti F., Zaccone P., Xiang M., Magro G., Di Mauro M., Di Marco R., Garotta G., and Meroni PL. Essential pathogenetic role for interferon (IFN)-gamma in Concanavalin A-induced T cell dependent hepatitis: Exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor Immunoglobulin fusion protein. *Cytokine*, 12 : 315-323, 2000

78) Nicoletti F., Di Marco R., Patti F., Zaccone P., L'Episcopo MR., Reggio E., Xiang M., Nicoletti A., and Reggio A. Short-term treatment of relapsing remitting multiple sclerosis patients with Interferon (IFN)-beta 1b transiently increases the blood levels of Interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1, IL-2, IL-4, and tumor necrosis factor- α . *Cytokine*, 12 : 682-687, 2000

79) Papaccio G., Nicoletti F., Pisanti FA., Bendtzen K., and Galdieri M. Prevention of spontaneous autoimmune diabetes by transferring in vitro antigen-pulsed dendritic cells. *Endocrinology*, 141 : 1500-1505, 2000

80) Gorrie MJ., Qasim FJ., Whittle CJ., Gillespie KM., Szeto C-C., Nicoletti F., Bolton EM., Bradley JA., and Mathieson PW. Exogenous type 1 cytokines Interferon-gamma and Interleukin-12 suppress the Th2 response induced by mercuric chloride. *Clin. Exp. Immunol.*, 121 ; 17-22, 2000

81) Meroni PL., Raschi E., Camera M., Testoni C., Nicoletti F., Tincani A., Khamastha MA., Balestrieri G., Tremoli E., Hess DC. Endothelial activation by aPL : a potential pathogenetic mechanism for clinical manifestation of the syndrome. *J. Autoimmun.*, 15 : 237-240, 2000

82) Nicoletti F., Di Marco R., Patti F., Nicoletti A., Leonardi C., Reggio E., Meroni PL., and Reggio A. The antiinflammatory cytokine Interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta 1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. *Autoimmunity*, 32 : 265-270, 2000

83) Nicoletti F., Di Marco R., Zaccone P., Salvaggio A., Magro G., Bendtzen K., and Meroni PL. Murine concanavalin A-induced hepatitis is prevented by interleukin (IL)-12 antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. *Hepatology*, 32 : 728-733, 2000

84) Nicoletti F., Di Marco R., Conget I., Gomis R., Edwards C. III., Papaccio G., Bendtzen K., and Sandler S. Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. *J. Autoimmunity*, 15 : 395-405, 2000

85) Nicoletti F., Conget I., Di Marco R., Speciale A.M., Morinigo R., Bendtzen K., and Gomis R. Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are

- increased in individuals at high risk of developing type 1 diabetes. *Diabetologia*, 44 : 309-311, 2001
- 86) Di Marco R., Puglisi G., Papaccio G., Nicoletti A., Patti F., Reggio A., Bendtzen K., and Nicoletti F. Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. *Multiple Sclerosis*, 7: 101-104, 2001
- 87) Di Marco R., Khademi M., Walstrom E., Iacobeus E., Salvaggio A., Caracappa S., Papoian R., Nicoletti F., and Olsson T. Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis. *J. Neuroimmunol.*, 116: 168-177, 2001
- 88) Panerai AE., Nicoletti F., Sacerdote P., Arvidsson L., Conget I., Gomis R., Bartorelli A. and Sandler S. MFP14, a multifunctional emerging protein with immunomodulatory properties, prevents spontaneous and recurrent autoimmune diabetes in NOD mice. *Diabetologia*, 44 : 839-847, 2001
- 89) Nicoletti F., Di Marco R., Patti F., Reggio E., Nicoletti A., Bendtzen K., and Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis. *Neurology*, 57 : 342-344, 2001
- 90) Nicoletti F., Di Marco R., Sacerdote P., Meroni PL., Mangano K., Edwards C. III, Bartorelli A., Bendtzen K., and Panerai A. Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. *Antimicrobial Agents and Chemotherapy*, 45: 1591-1594, 2001
- 91) Patti F., Cataldi ML., Nicoletti F., Reggio E., Nicoletti A., and Reggio A. Combination therapy with cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. *J. Neurol Neurosurg. Psychiatr.* 71: 404-407, 2001
- 92) Ablake M., Itoh M., Kaneko T., Iimura A., Nakamura Y., Meroni P., and Nicoletti F. Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. *Eur. J. Pharmacol.*, 23, 450: 209-212, 2002
- 93) Nicoletti F., Conget I., Di Mauro M., Mazzarino MC., Bendtzen K., Messina A., and Gomis R. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type 1 diabetes mellitus patients and subjects at risk of developing the disease. *Diabetologia*, 45: 1107-1110, 2002
- 94) Papaccio G., Nicoletti F., Pisanti FA., Galdieri M., and Bendtzen K. An imidazoline compound completely counteracts interleukin-1 [beta] toxic effects to rat pancreatic islet [beta] cells. *Mol. Med.*, 9: 536-545, 2002
- 95) Drage M., Zaccone P., Phillips JM., Nicoletti F., Dawson J., Andrew Bradley J., and Cooke A. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevents autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. *Transplantation*, 74: 611-619, 2002
- 96) Li L., Itoh M., Ablake M., Nacri B., Benbdtzen K., and Nicoletti F. Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6. *Clin. Immunol.*, 102: 135-137, 2002
- 97) Zaccone P., Fehervari Z., Blanchard L., Nicoletti F., Edwards CC 3rd, and Cooke A. Autoimmune thyroid disease induced by thyroglobulin and lipopolysaccharide is inhibited by soluble TNF receptor type 1. *Eur. J. Immunol.*, 32: 1021-1028, 2002
- 98) Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M, Castiglione M, Mangano K, Busceti CL, Nicoletti FR, Bacon K, Tusche M, Valenti O, Conn PJ, Bruno V, Nicoletti F. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. *J. Neurosci.*, 22: 5403-11, 2002
- 99) Pennisi G, Alagona G, Rapisarda G, Nicoletti F, Costanzo E, Ferri R, Malaguarnera M, Bella R.: Transcranial magnetic stimulation after pure motor stroke. *Clin Neurophysiol.* 2002Oct;113(10):1536-43.
- 100) Recasens M., Aguilera E., Morinigo R., Casamitjana R., Nicoletti F., Gomis R., and Conget I. Insulin lipro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. *Diabetes Res. Clin. Pract.*, 3: 153-159, 2003
- 101) Nicoletti F., Di Marco RD, Papaccio G., Conget I., Gomis R., Bernardini R., Sims JE., Shoenfeld Y., and Bendtzen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18-binding protein: Fc construct. *Eur. J. Immunol.*, 8: 2278-2286, 2003
- 102) Kaneko T., Itoh M., Nakamura Y., Iimura A., Hayashi S., Takahashi K., Stivala F., Bendtzen K., and Nicoletti F. Proinflammatory effects of exogenously administered IL-10 in experimental autoimmune orchitis. *Cytokine*, 22: 50-53, 2003

- 103) Di Marco R., Mangano K., Quattrocchi C., Musumeci R., Speciale AM., Papaccio G., Buschard K., Bendtzen K., and Nicoletti F. Curative effects of sodium fusidate on the development of dinitrobenzene sulfonic acid (DNB)-induced colitis in rats. *Clin. Immunol.*, 109: 266-271, 2003
- 104) Cantarella G., Risuglia N., Lombardo G. Lempereur L., Nicoletti F., Memo M., and Bernardini R. Protective effects of estradiol on TRAIL-induced apoptosis in human oligodendrocytic cell line: evidence for multiple sites of interactions. *Cell Death Differ.*, 11: 503-511, 2004
- 105) Lgssiar A., Hassan M., Schott-Ohly P., Friesen N., Nicoletti F., Trepicchio WL., and Gleichmann H. Interleukin-11 inhibits NF-kappaB and AP1 activation in islets and prevents diabetes induced with streptozotocin in mice. *Exp. Biol. Med.*, 229: 425-436, 2004
- 106) Di Paola R., Di Marco R., Mazzon E., Genovese T., Bendtzen K., Macrì B., Nicoletti F., and Cuzzocrea S. Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal, *Clin. Immunol.*, 113: 64-73, 2004
- 107) Di Marco R, Mangano K, Quattrocchi C, Amato F, Nicoletti F, Buschard K. Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. *APMIS*. 2004 Oct;112(10):651-5.
- 108) Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, Nicoletti F. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. *Arzneimittelforschung*. 2004;54(12):881-6.
- 109) Aguilera E, Casamitjana R, Ercilla G, Oriola J, Nicoletti F, Gomis R, Conget I. Clinical characteristics, beta-cell function, HLA class II and mutations in MODY genes in non-paediatric subjects with Type 1 diabetes without pancreatic autoantibodies. *Diabet Med*. 22:137-43, 2005
- 110) Zaccone P, Phillips J, Conget I, Cooke A, Nicoletti F. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. *Clin Immunol*. 115:74-9, 2005
- 111) Papaccio G, Graziano A, Valiante S, D'Aquino R, Travali S, Nicoletti F. Interleukin (IL)-1beta toxicity to islet beta cells: Efaroxan exerts a complete protection. *J Cell Physiol*. 203:94-102, 2005
- 112) De Carvalho Bittencourt M, Herren S, Graber P, Vilbois F, Pasquali C, Berney C, Plitz T, Nicoletti F, Kosco-Vilbois MH. Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. *Eur J Immunol*. 35:1501-9, 2005
- 113) Cvetkovic I, Al-Abed Y, Milijkovic D, Maksimovic-Ivanic D, Roth J, Bacher M, Lan HY, Nicoletti F, Stosic-Grujcic S. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. *Endocrinology* 146:2942-51, 2005
- 114) Conget I, Aguilera E, Pellitero S, Naf S, Bendtzen K, Casamitjana R, Gomis R, Nicoletti F. Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial. *Diabetologia*. 48:1464-8, 2005.
- 115) Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz CN, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. *J Biol Chem*. 2005 Nov 4;280(44):36541-4. Epub 2005 Aug 22.
- 116) Auci D, Nicoletti F, Mangano K, Pieters R, Nierkens S, Morgan L, Offner H, Frincke J, Reading C. Anti-inflammatory and Immune Regulatory Properties of 5-Androsten-3{beta}, 17{beta}-Diol (HE2100), and Synthetic Analogue HE3204: Implications for Treatment of Autoimmune Diseases. *Ann N Y Acad Sci*. 1051:730-42, 2005
- 117) Nicoletti F, Creange A, Orlikowski D, Bolgert F, Mangano K, Metz C, Di Marco R, Al Abed Y. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. *J Neuroimmunol*. 2005 Nov;168:168-74.
- 118) Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC. Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. *Cancer Biol Ther*. 2005; 4:1192-4.
- 119) Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, Quattrocchi C, Nicoletti F. Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity.

Arzneimittelforschung. 2005;55:581-7.

120) Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, Salvetti M, Nicoletti F, Pozzilli C.: Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. *J Neurol Neurosurg Psychiatry*. 2005 Feb;76(2):272-5.

121) Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, Di Marco R, Signorelli S, Scalia G, Zignego AL, De Re V, Mazzarino MC, Nicoletti F. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. *Oncol Rep*. 2006;15:1305-8.

122) Malaguarnera L, Di Rosa M, Zambito AM, dell'Ombra N, Nicoletti F, Malaguarnera M Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. *Gut* 2006, 55:1313-20.

123) Di Rosa M, Dell'Ombra N, Zambito AM, Malaguarnera M, Nicoletti F, Malaguarnera L.: Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia.. *Eur J Neurosci*. 2006 May;23(10):2648-56.

124) Stosic-Grujicic S, Cvetkovic I, Mangano K, Fresta M, Maksimovic-Ivanic D, Harhaji L, Popadic D, Momcilovic M, Miljkovic D, Kim J, Al-Abed Y, Nicoletti F. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. *J Pharmacol Exp Ther*. 2007, 320:1038-49.

125) Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, Donia M, Al Abed Y, Kim J, Nicoletti F, Stosic-Grujicic S, Claesson M. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. *Clin Immunol*. 2007;123:311-23.

126) Perdichizzi A, Nicoletti F, La Vignera S, Barone N, D'Agata R, Vicari E, Calogero AE Effects of tumour necrosis factor-alpha on human sperm motility and apoptosis. *J Clin Immunol*. 2007 Mar;27(2):152-62.

127) Aljabari B, Calogero AE, Perdichizzi A, Vicari E, Karaki R, Lahloub T, Zatari R, El-Abed K, Nicoletti F, Miller EJ, Pavlov VA, Al-Abed Y. Imbalance in seminal fluid MIF indicates male infertility. *Mol Med*. 2007 Mar-Apr;13(3-4):199-202.

128) Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF. Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. *J Neuroimmunol*. 2007 Oct;190(1-2):8-17.

129) Galle P, Jensen L, Andersson C, Cuzzocrea S, Di Paola R, Nicoletti F, Svenson M, Bendtzen K, Thomsen AR, Hansen MB. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. *Int Immunopharmacol*. 2007 Dec 15;7(13):1704-13. Epub 2007 Sep 21.

130) Claesson MH, Nicoletti F, Stosic-Grujicic S, Doria A, Zampieri S. Interactions between infections and immune-inflammatory cells in type 1 diabetes mellitus and inflammatory bowel diseases: evidences from animal models. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1 Suppl 48):S8-11. Review.

131) Maksimovic-Ivanic D, Mijatovic S, Harhaji L, Miljkovic D, Dabideen D, Fan Cheng K, Mangano K, Malaponte G, Al-Abed Y, Libra M, Garotta G, Nicoletti F, Stosic-Grujicic S. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. *Mol Cancer Ther*. 2008 Mar;7(3):510-20.

132) Mangano K, Dati G, Quattrocchi C, Proietti L, Mazzarino C, Di Marco R, Bendtzen K, Greco B, Zaratin P, Nicoletti F. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barré syndrome. *J Neuroimmunol*. 2008 May 30;196(1-2):107-15.

133) Mangano K, Sardesai N, D'Alcamo M, Libra M, Malaguarnera L, Donia M, Bendtzen K, Meroni P, Nicoletti F. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. *Eur J Pharmacol*. 2008 May 31;586(1-3):313-21.

134) Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, Miljkovic D, Metz C, Mangano K, Papaccio G, Al-Abed Y, Nicoletti F. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. *J Cell Physiol*. 2008 Jun;215(3):665-75.

135) Mijatovic S, Maksimovic-Ivanic D, Mojic M, Malaponte G, Libra M, Cardile V, Miljkovic D, Harhaji L, Dabideen D, Cheng KF, Bevelacqua Y, Donia M, Garotta G, Al-Abed Y, Stosic-Grujicic S, Nicoletti F. Novel nitric oxide-donating compound (S,R)-

- 3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. *Nitric Oxide*. 2008 Sep;19(2):177-83.
- 136) Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL, Carbone A. Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. *J Hepatol*. 2008 Aug;49(2):170-4.
- 137) Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. *Autoimmun Rev*. 2008 Aug 19.
- 138) Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. *Expert Opin Ther Targets*. 2008 Sep;12(9):1139-65.
- 139) McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Bäsecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahan M, Evangelisti C, Martelli AM. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. *Leukemia* 2008 Nov;22(11):2080-90.
- 140) Mangano K, Sardesai NY, Quattrocchi C, Mazzon E, Cuzzocrea S, Bendtzen K, Meroni PL, Kim JJ, Nicoletti F. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. *Br J Pharmacol*. 2008 Nov;155(5):722-30.
- 141) Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. *Leukemia*. 2009 Jan;23(1):25-42.
- 142) Nicoletti F, Lamenta C, Donati S, Spada M, Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. *Clin Exp Immunol*. 2009 Jan;155(1):28-34.
- 143) Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojasavljevic N, Nicoletti F, Drulovic J. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. *J Neuroimmunol*. 2009 Feb 15;207(1-2):101-6.
- 144) Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. *Cell Cycle*. 2009 May 1;8(9):1352-8. Review.
- 145) Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. *J Mol Med*. 2009 Jul;87(7):679-95. Review.
- 146) Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, Al-Abed Y, Libra M, Garotta G, Stosic-Grujicic S, Nicoletti F. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. *Mol Cancer Ther*. 2009 May 5.
- 147) Donia M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Mangano K, Tumino S, Biondi A, Basile F, Al-Abed Y, Stosic-Grujicic S, Nicoletti F. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. *Eur J Pharmacol*. 2009 Aug 1;615(1-3):228-33.
- 148) Donia M, Mangano K, Amoroso A, Mazzarino MC, Imbesi R, Castrogiovanni P, Coco M, Meroni P, Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. *J Autoimmun*. 2009 Sep;33(2):135-40.
- 149) Ahlem C, Auci D, Mangano K, Reading C, Frincke J, Stickney D, Nicoletti F. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. *Ann N Y Acad Sci*. 2009 Sep;1173:781-90.
- 150) Nicoletti F, Conrad D, Wang A, Pieters R, Mangano K, van Heeckeren A, White SK, Frincke J, Reading CL, Auci DL, Stickney D. 16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. *Clin Exp Immunol*. 2009 Dec;158(3):308-16.
- 151) McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. Emerging Raf inhibitors. *Expert Opin Emerg Drugs*. 2009 Dec;14(4):633-48. Review.
- 152) Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L, Signorelli S, Magro G, Muzio V, Greco B, Zaratini P, Meroni P, Zappia M, Nicoletti F. Variable effects of

- cyclophosphamide in rodent models of experimental allergic encephalomyelitis. *Clin Exp Immunol.* 2010 Feb;159(2):159-68.
- 153) Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Travali S, McCubrey JA, Canevari S, Libra M. Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. *Cell Cycle.* 2010 Feb 6;9(3).
- 154) Mijatovic S, Maksimovic-Ivanic D, Timotijevic G, Miljkovic D, Donia M, Libra M, Coco M, McCubrey J, Al-Abed Y, Korac A, Stosic-Grujicic S, Nicoletti F. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. *Free Radic Biol Med* 2010 Jan 28.
- 155) Auci DL, Mangano K, Destiche D, White SK, Huang Y, Boyle D, Frincke J, Reading CL, Nicoletti F. Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis. *Int J Mol Med* 2010 Apr 25 625-33
- 156) Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. *Cell Cycle.* 2010 Apr 10;9(8).
- 157) Libra M, Polesel J, Russo AE, De Re V, Cinà D, Serraino D, Nicoletti F, Spandidos DA, Stivala F, Talamini R. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? *Int J Oncol.* 2010 Jun;36(6):1331-40. Review.
- 158) McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. Emerging MEK inhibitors. *Expert Opin Emerg Drugs.* 2010 Jun;15(2):203-23.
- 159) Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. *Cell Cycle.* 2010 May;9(9):1839-46.
- 160) Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. *Cell Cycle.* 2010 May;9(9):1781-91.
- 161) Marconi A, Candido S, Talamini R, Libra M, Nicoletti F, Spandidos DA, Stivala F, Proietti L: Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey. *Mol Med Report.* 2010 Jul-Aug;3(4):561-4
- 162) Donia M, Cacopardo B, Libra M, Scalia G, McCubrey JA, Nicoletti F. New perspectives in HCV therapy: entry inhibitors. *Recent Pat Antiinfect Drug Discov.* 2010 Nov 1;5(3):181-94.
- 163) Donia M, McCubrey JA, Bendtzen K, Nicoletti F.: Potential use of rapamycin in HIV infection. *Br J Clin Pharmacol.* 2010 Dec;70(6):784-93.
- 164) Libra, M. , Torrisi, E., Castellano, G., Nicoletti, F., Malaponte, G., Mazzarino, M.C., Marconi, A., Proietti, L., Militello, L., Bonavida, B., Stivala, F., Canevari, S.: Computational evaluation of yin yang 1 transcript levels in the spectrum of B-cell neoplasia. *Forum on Immunopathological Diseases and Therapeutics Volume 1, Issue 1-2, 2010, Pages 115-125*
- 165) Canevari, S., Napoli, C., Nicoletti, F., Spandidos, D.A.: Role of YY1 in pathogenesis of cancer (Note) *Forum on Immunopathological Diseases and Therapeutics Volume 1, Issue 1-2, 2010, Pages 145-148*
- 166) McCubrey, J.A. , Abrams, S.L., Chappell, W.H., Steelman, L.S., Ligresti, G., Vella, N., Marconi, A., Proietti, L., Nicoletti, F., Libra, M., Stivala, F.: Rationale for targeting of YY1 in drug-resistant leukemias. *Forum on Immunopathological Diseases and Therapeutics Volume 1, Issue 1-2, 2010, Pages 65-79*
- 167) Ahlem CN, Page TM, Auci DL, Kennedy MR, Mangano K, Nicoletti F, Ge Y, Huang Y, White SK, Villegas S, Conrad D, Wang A, Reading CL, Frincke JM. Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. *Steroids.* 2011 Jan;76(1-2):145-55.
- 168) Conrad D, Wang A, Pieters R, Nicoletti F, Mangano K, van Heeckeren AM, White SK, Frincke JM, Reading CL, Stickney D, Auci DL. HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression. *J Inflamm (Lond).* 2010 Oct 30;7:52.
- 169) Donia M, Mangano K, Quattrocchi C, Fagone P, Signorelli S, Magro G, Sfacteria A, Bendtzen K, Nicoletti F. Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents.

Scand J Immunol. 2010 Nov;72(5):396-407.

170) Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, Donia M, Cataldo AD, Al-Abed Y, Cheng KF, Stosic-Grujicic S, Nicoletti F. Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. *J Cell Physiol*. 2010 Nov 10.

171) Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, Nicoletti F, Cinatl J. Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells. *Neoplasia*. 2010 Dec;12(12):1023-30.

172) Nicoletti F, Auci DL, Mangano K, Flores-Riveros J, Villegas S, Frincke JM, Reading CL, Offner H. 5-androstenediol ameliorates pleurisy, septic shock, and experimental autoimmune encephalomyelitis in mice. *Autoimmune Dis*. May 18;2010:757432. 2010

173) Fagone P, Mangano K, Quattrocchi C, Motterlini R, Di Marco R, Magro G, Penacho N, Romao CC, Nicoletti F. Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. *Clin Exp Immunol*. 2011 Jan 14.

174) Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, Fagone P, Caponnetto S, Al-Abed Y, McCubrey J, Stosic-Grujicic S, Nicoletti F. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. *Cell Cycle*. 2011 Feb 1;10(3).

175) McCubrey JA, Steelman LS, Kempf CR, Chappell W, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. Therapeutic Resistance Resulting from Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways. *J Cell Physiol*. 2011 Feb 1

176) Kosiewicz MM, Auci DL, Fagone P, Mangano K, Caponnetto S, Tucker CF, Azeem N, White SK, Frincke JM, Reading CL, Nicoletti F. HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse. *Eur J Pharmacol*. 2011 Feb 28.

177) Nicoletti A, Fagone P, Donzuso G, Mangano K, Dibilio V, Caponnetto S, Bendtzen K, Zappia M, Nicoletti F. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. *Cytokine*. 2011 May 6.

178) Ahlem CN, Auci DL, Nicoletti F, Pieters R, Kennedy MR, Page TM, Reading CL, Enioutina EY, Frincke JM. Pharmacology and immune modulating properties of 5-androstene-3 β ,7 β ,17 β -triol, a DHEA metabolite in the human metabolome. *J Steroid Biochem Mol Biol*. 2011 May 5.

179) Donia M, Anzaldi M, Di Marco R, Libra M, Mangano K, Fagone P, Galvagna S, Di Gregorio P, Nicoletti F. Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. *Int J Mol Med*. 2011 May 20.

180) Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K. mTOR as a multifunctional therapeutic target in HIV infection. *Drug Discov Today*. 2011 Aug;16(15-16):715-21

181) Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. *Oncotarget*. 2011 Jul;2(7):538-50.

182) Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA.: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. *Aging (Albany NY)*. 2011 Mar;3(3):192-222

183) Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*. 2011 Mar;2(3):135-64.

184) Steelman LS, Martelli AM, Nicoletti F, McCubrey JA. Exploiting p53 status to

enhance effectiveness of chemotherapy by lowering associated toxicity. *Oncotarget*. 2011 Mar;2(3):109-12.

185) Coco M, Perciavalle V, Maci T, Nicoletti F, Di Corrado D, Perciavalle V. The second-to-fourth digit ratio correlates with the rate of academic performance in medical school students. *Mol Med Report*. 2011 May-Jun;4(3):471-6.

186) Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. *Leukemia*. 2011 Jul;25(7):1064-79.

187) Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.: Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. *Leukemia*. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66.

188) Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, Donia M, Di Cataldo A, Al-Abed Y, Cheng KF, Stosic-Grujicic S, Nicoletti F. :Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells. *J Cell Physiol*. 2011 Jul;226(7):1803-12.

189) Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.: Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. *Cell Cycle*. 2011 Sep 1;10(17):3003-15.

190) Canducci F, Ceresola ER, Saita D, Al-Abed Y, Garotta G, Clementi M, Nicoletti F. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. *Antiviral Res*. 2011 Sep;91(3):292-5.

191) Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. *Immunology*. 2011 Oct;134(2):123-39.

192) McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Bäsecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM. Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. *Curr Pharm Des*. 2012 Jan 19.

193) Fagone P, Mangano K, Coco M, Perciavalle V, Garotta G, Romao CC, Nicoletti F. Therapeutic potential of carbon monoxide in multiple sclerosis. *Clin Exp Immunol*. 2012 Feb;167(2):179-87. doi: 10.1111/j.1365-2249.2011.04491.x. Review. 168)

194) Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, Mangano K, Zocca MB, Alabed Y, McCubrey JA, Nicoletti F. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. *Cell Cycle*. 2012 Mar 15;11(6).

195) Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, Mijatovic S. Resistance to TRAIL and how to surmount it. *Immunol Res*. 2012 Mar 11

196) Donia M, Mangano K, Fagone P, De Pasquale R, Dinotta F, Coco M, Padron J, Al-Abed Y, Giovanni Lombardo GA, Maksimovic-Ivanic D, Mijatovic S, Zocca MB, Perciavalle V, Stosic-Grujicic S, Nicoletti F. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. *Oncol Rep*. 2012 Aug;28(2):682-8

197) Mangano K., Fagone P., Di Mauro M., Ascione E., Maiello V., Milicic T., Jotic A., Lalic N.M., Saksida T., Stojanovic I., Selmi C., Farina C., Stosic-Grujicic S., Meroni P., Nicoletti F. The immunobiology of apotransferrin in type 1 diabetes. *Clin Exp Immunol*. 2012 Sep;169(3):244-252

198) Fagone P, Di Rosa M, Palumbo M, De Gregorio C, Nicoletti F, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. *Inflamm Res*. 2012 Oct;61(10):1131-9

199) Stojanovic I, Saksida T, Nikolic I, Nicoletti F, Stosic-Grujicic S. Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro. *Clin Exp Immunol*. 2012 Aug;169(2):156-63

200) Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA, Nicoletti F. Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. *Basic Clin Pharmacol Toxicol*. 2012 Jul 4.

201) Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y,

- McCubrey JA, Nicoletti F. Therapeutic Potential of NO-Modified Drugs in Colon Cancer Cells. *Mol Pharmacol* 2012 Oct;82(4):700-10.
- 202) Di Rosa M, Mangano K, De Gregorio C, Nicoletti F, Malaguarnera L. Association of chitotriosidase genotype with the development of non-alcoholic fatty liver disease. *Hepatology Res.* 2012 Jun 22.
- 203) McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget.* 2012 Sep;3(9):954-87.
- 204) Nicoletti F, Philippens I, Fagone P, Ahlem CN, Reading CL, Frincke JM, Auci DL. 17 α -Ethinyl-androst-5-ene-3 β ,7 β ,17 β -triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease. *Parkinsons Dis.* 2012;2012:969418.
- 205) McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget.* 2012 Oct;3(10):1068-111.
- 206) Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, Andersen MH, Svane IM. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. *Oncoimmunology.* 2012 Dec 1;1(9):1476-1483.
- 207) McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN. Advances in targeting signal transduction pathways. *Oncotarget.* 2012 Dec;3(12):1505-21.
- 208) Saksida Tamara, Miljkovic Djordje, Timotijevic Gordana, Stojanovic Ivana, Mijatovic Sanja, Fagone Paolo, Mangano Katia, Mammana Santa, Farina Claudio, Ascione Ester, Maiello Valentina, Nicoletti F, Stosic-Grujicic Stanislava. Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. *Journal of neuroimmunolog.* 2013; 262:72-78
- 209) Di Rosa M, Mangano K, De Gregorio C, Nicoletti F, Malaguarnera L. Association of chitotriosidase genotype with the development of non-alcoholic fatty liver disease.. *Hepatology research.* 2013; 43:267-275
- 210) Nikolic I., Saksida T., Vujicic M., Stojanovic I., Nicoletti F, Stosic-Grujicic S. Carbon monoxide-releasing molecule CORM-A1 ameliorates islet-directed autoimmunity in mice. *Diabetologia.* 2013; 56: S228
- 211) Fagone Paolo, Donia Marco, Mangano Katia, Quattrocchi Cinzia, Mammana Santa, Coco Marinella, Libra Massimo, McCubrey James A., Nicoletti F. Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. *Basic & clinical pharmacology & toxicology,* 2013; 112:63-69
- 212) Petković F, Blaževski J, Momčilović M, Timotijević G, Zocca MB, Mijatović S, Maksimović-Ivanic D, Mangano K, Fagone P, Stošić-Grujičić S, Nicoletti F, Miljković D. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2013 Jun 15;259(1-2):55-65
- 213) Fagone P, Patti F, Mangano K, Mammana S, Coco M, Touil-Boukoffa C, Chikovani T, Di Marco R, Nicoletti F. Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. *J Neuroimmunol.* 2013 May 25
- 214) Fagone P, Mangano K, Mammana S, Quattrocchi C, Magro G, Coco M, Imene S, Di Marco R, Nicoletti F. Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan. *Lupus,* 2014.
- 215) McCubrey J. A., Steelman L. S., Bertrand F. E., Davis N. M., Abrams S. L., Montalto G., D'Assoro A. B., Libra M., Nicoletti F, Maestro R., Basecke J., Cocco L., Cervello M., Martelli A. M. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

- Leukemia, vol. 28, p. 15-33, 2014.
- 216) Fagone P, Muthumani K, Mangano K, Magro G, Meroni PL, Kim JJ, Sardesai NY, Weiner DB, Nicoletti F. VGX-1027 modulates genes involved in the LPS-induced TLR-4 activation and in a murine model of Systemic Lupus Erythematosus. *Immunology* 2014.
- 217) Mangano K, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, Di Rosa M, Malaguarnera L, Coco M, Magro G, Di Marco R, Nicoletti F. Hypomethylating Agent 5-Aza-2'-deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models. *Journal Of Cellular Physiology*, 2014.
- 218) McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Libra M, Nicoletti F, D'Assoro AB, Cocco L, Martelli AM, Steelman LS. Targeting breast cancer initiating cells: advances in breast cancer research and therapy . *Advances In Biological Regulation*, vol. 56, p. 81-107, 2014.
- 219) Momčilović M, Mangano K, Jevtić B, Mammana S, Stošić-Grujičić S, Nicoletti F, Miljković D. Saquinavir-NO inhibits IL-6 production in macrophages. *Basic & Clinical Pharmacology & Toxicology*, vol. 115, p. 499-506, 2014.
- 220) McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, Libra M, Nicoletti F, Cocco L, Martelli AM, Steelman LS. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. *Advances In Biological Regulation*, vol. 54, p. 176-196, 2014.
- 221) Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. . *Oncotarget*, vol. 5, p. 4603-4650. 2014.
- 222) Fagone P, Mangano K, Mammana S, Cavalli E, Di Marco R, Barcellona ML, Salvatorelli L, Magro G, Nicoletti F. Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. *Clin Immunol*. 2015 Apr;157(2):198-204.
- 223) Soufli I, Toumi R, Rafa H, Amri M, Labsi M, Khelifi L, Nicoletti F, Touil-Boukoffa C. Crude extract of hydatid laminated layer from *Echinococcus granulosus* cyst attenuates mucosal intestinal damage and inflammatory responses in Dextran Sulfate Sodium induced colitis in mice. *J Inflamm (Lond)*. 2015 Mar 17;12:19.
- 224) Fagone P, Mangano K, Quattrocchi C, Cavalli E, Mammana S, Lombardo GA, Pennisi V, Zocca MB, He M, Al-Abed Y, Nicoletti F. Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir. *Basic Clin Pharmacol Toxicol*. 2015 Apr 23
- 225) Conway TF, Hammer L, Furtado S, Mathiowitz E, Nicoletti F, Mangano K, Egilmez NK, Auci DL. Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease. *J Crohns Colitis*. 2015 May 18.
- 226) Fagone P, Mangano K, Mammana S, Pesce A, Pesce A, Caltabiano R, Giorlandino A, Portale TR, Cavalli E, Lombardo GA, Coco M, Puleo S, Nicoletti F. Identification of novel targets for the diagnosis and treatment of liver fibrosis. *Int J Mol Med*. 2015 Sep;36(3):747-52.
- 227) Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, Andersen MH, Thor Straten P, Svane IM. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. *Cancer Res*. 2015 Sep 15;75(18):3747-59.
- 228) Maksimovic-Ivanic D, Mojic M, Bulatovic M, Radojkovic M, Kuzmanovic M, Ristic S, Stosic-Grujicic S, Miljkovic D, Cavalli E, Libra M, Fagone P, McCubrey J, Nicoletti F, Mijatovic S. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. *Leuk Res*. 2015 Oct;39(10):1088-95.
- 229) Fagone P, Nicoletti F, Salvatorelli L, Musumeci G, Magro G. Cyclin D1 and Ewing's sarcoma/PNET: A microarray analysis. *Acta Histochem*. 2015 Sep 9.
- 230) Fagone P, Nicoletti F, Vecchio GM, Parenti R, Magro G. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis. *Acta Histochem*. 2015 Oct;117(8):820-3.
- 231) Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, Bagarazzi ML, Muthumani K, Boyer J, Agarwal V, Nicoletti F, Bart S, Kim JJ, Weiner DB, Sardesai NY. Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. *Clinical Pharmacology In Drug Development*, 2016.
- 232) Fagone P, Nunnari G, Lazzara F, Longo A, Cambria D, Distefano G, Palumbo M,

- Nicoletti F, Malaguarnera L, Di Rosa M. Induction of OAS gene family in HIV monocyte infected patients with high and low viral load.. *Antiviral Research*, vol. 131, p. 66-73, 2016
- 233) Fagone P, Mangano K, Pesce A, Portale TR, Puleo S, Nicoletti F. Emerging therapeutic targets for the treatment of hepatic fibrosis. *Drug Discov Today*. 2015 Oct 30.
- 234) Fagone P, Mangano K, Di Marco R, Touil-Boukoffa C, Chikovan T, Signorelli S, Lombardo GA, Patti F, Mammanna S, Nicoletti F. Expression of DNA methylation genes in secondary progressive multiple sclerosis. *J Neuroimmunol*. 2016 Jan 15;290:66-9.
- 235) Pappalardo F, Russo G, Candido S, Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F, Libra M. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. *PLoS One*. 2016 Mar 25;11(3)
- 236) Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA. The therapeutic potential of mTOR inhibitors in breast cancer. *Br J Clin Pharmacol*. 2016 Nov;82(5):1189-1212.
- 237) McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmioli S, Cocco L, Martelli AM. Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. *Biochim Biophys Acta*. 2016 Dec;1863(12):2942-2976
- 238) Steelman LS, Fitzgerald T, Lertpiriyapong K, Cocco L, Follo MY, Martelli AM, Neri LM, Marmioli S, Libra M, Candido S, Nicoletti F, Scalisi A, Fenga C, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Milella M, Tafuri A, Demidenko Z, Abrams SL, McCubrey JA. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. *Curr Pharm Des*. 2016 Mar 4.
- 239) Nunnari G, Fagone P, Condorelli F, Nicoletti F, Malaguarnera L, Di Rosa M. CD4+T-cell gene expression of healthy donors, HIV-1 and elite controllers: Immunological chaos. *Cytokine*, vol. 83, p. 127-135. 2016
- 240) Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, Avola R, Salmeri M, Nicoletti F, Anfuso CD. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. *Front Pharmacol*. 2017 Jan 6;7:519.
- 241) Nikolic I, Stojanovic I, Vujcic M, Fagone P, Mangano K, Stosic-Grujicic S, Nicoletti F, Saksida T. Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. *Immunobiology*. 2017 Feb;222(2):272-279
- 242) Magro G, Salvatorelli L, Alaggio R, D'Agata V, Nicoletti F, Di Cataldo A, Parenti R. Diagnostic utility of cyclin D1 in the diagnosis of small round blue cell tumors in children and adolescents. *Hum Pathol*. 2017 Feb;60:58-65
- 243) McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Nicoletti F, Falzone L, Candido S, Libra M. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. *Oncotarget*. 2017 Feb 21;8(8):14221-14250.
- 244) Nikolic I, Stojanovic I, Vujcic M, Fagone P, Mangano K, Stosic-Grujicic S, Nicoletti F, Saksida T. Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. *Immunobiology*. 2017 Feb;222(2):272-279
- 245) McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM, Cocco L, Ratti S, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Lombardi P, Nicoletti F, Candido S, Libra M, Montalto G, Cervello M. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. *Aging (Albany NY)*. 2017 Jun 12;9(6):1477-1536.
- 246) Donia M, Harbst K, Van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir S, Ellebaek E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Acquired immune resistance follows complete tumor regression without loss of target antigens or IFN- γ signaling. *Cancer Res*. 2017 Jun 27
- 247) Fagone P, Caltabiano R, Russo A, Lupo G, Anfuso CD, Basile MS, Longo A, Nicoletti F, De Pasquale R, Libra M, Reibaldi M. Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. *Sci Rep*. 2017 Mar 17;7:44564.

- 248) Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S, Nicoletti F HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. International Journal Of Cancer, vol. 140, p. 1713-1726. 2017
- 249) Mangano K, Vergalito F, Mammanna S, Mariano A, De Pasquale R, Meloscia A, Bartollino S, Guerra G, Nicoletti F, Di Marco R. Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Exp Ther Med. 2017 Sep;14(3):2439-2444.
- 250) Mangano K, Cavalli E, Mammanna S, Basile MS, Caltabiano R, Pesce A, Puleo S, Atanasov AG, Magro G, Nicoletti F, Fagone P. Involvement of the Nrf2/HO-1/CO axis and therapeutic intervention with the CO-Releasing Molecule CORM-A1, in a murine model of Autoimmune Hepatitis. J Cell Physiol. 2017 Oct 15.

Catania, 31/10/2017

In fede

A handwritten signature in blue ink, reading "Ferdinando Nicoletti". The signature is written in a cursive style and is centered on the page.